Report: Pfizer won't buy Brazil's Teuto; FDA warns on risk of heart-drug combo;

@FiercePharma: Don't overreact to meta-analysis, FDA says. Report | Follow @FiercePharma

> Pfizer failed to reach an agreement to buy Brazilian generic drugmaker Teuto as the two parties differed over the price, Folha de S. Paulo reported. News

> The FDA has warned about the risk of a rare type of muscle injury seen when the cholesterol drug simvastatin is combined with the anti-arrhythmia medicine amiodarone. Report

> Patients who took part in Teva Pharmaceutical Industries' testing of its flagship drug Copaxone against Lou Gehrig's disease are suing the generic drug giant, demanding it reveal the results of the trial. Item

> Abbott Laboratories, which last week completed its acquisition of the India-based Piramal Healthcare's pharma business, will maintain the business as an independent unit within its newly created established products division. Article

> Bulgarians are paying too much for their medicines, according to representatives of the Bulgarian Association of Research-Based Pharmaceutical Manufacturers. Article

> U.S. biopharmaceutical companies have 395 new drugs and vaccines to fight infectious diseases in late-stage development, a new report says. Report

> China's plans to vaccinate 100 million children and come a step closer to eradicating measles has set off a popular outcry that highlights widening public distrust of the authoritarian government after repeated health scandals. Story

> Bausch + Lomb has named Daniel Wechsler as corporate vice president and global president of its pharmaceuticals business. Item

Biotech News

@FierceBiotech: Four drugs look to pass FDA muster this month. Report |  Follow @FierceBiotech

> Santarus snags U.S. rights to Pharming's Rhucin in $20 million pact. Report

> Seattle Genetics will shelve AML drug after PhIIb failure. Article 

> Roche, Ipsen diabetes drug sidelined by Phase III safety issues. News

> Novartis meningitis vax promising in Phase III. Story

> Third Rock gathers $426M for new biotech investments. Report

> Relypsa banks $70M Series B for pivotal trial work. News

Biotech IT News

> IT becomes vendor ops inspector via SaaS. News

> FDA takes second look at meta-analysis. Item

> New media use rising in subject recruitment. Story

> Cato lists five keys to success in adaptive trials. Article

> Video-game makers and clinicians push motion-capture tech. News

And Finally... The genetic predisposition to obesity can be reduced by an average of 40 percent through increased physical activity, researchers found. News

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.